SCHEMBL1764514

SCHEMBL1764514

CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNPAT O15228 2/20 0.54
ALOX15 P16050 2/20 0.47
BLM P54132 2/20 0.47
KDM4E B2RXH2 1/20 0.47
MAPT P10636 1/20 0.47
THRB P10828 1/20 0.47
NFKB1 P19838 1/20 0.47
PTGS2 P35354 1/20 0.47
THPO P40225 1/20 0.47
RECQL P46063 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ALDH1A1 P00352 1/20 0.46
BMP1 P13497 1/20 0.46
KMT2A Q03164 2/20 0.46
SIRT5 Q9NXA8 1/20 0.44
CA2 P00918 4/20 0.43
CA1 P00915 3/20 0.43
FOLH1 Q04609 4/20 0.43
RIMKLA Q8IXN7 1/20 0.43
NAALAD2 Q9Y3Q0 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764511 1.00 GNPAT (0.54) GNPATALOX15BLMKDM4EMAPT
SCHEMBL30717266 0.95 GNPAT (0.57) GNPATALOX15BLMKDM4EMAPT
SCHEMBL2248726 0.95 GNPAT (0.57) GNPATALOX15BLMKDM4EMAPT
SCHEMBL287577 0.93 ALOX15 (0.53) GNPATALOX15BLMKDM4EMAPT
SCHEMBL287578 0.93 ALOX15 (0.53) GNPATALOX15BLMKDM4EMAPT
SCHEMBL6026388 0.93 ALOX15 (0.53) GNPATALOX15BLMKDM4EMAPT
SCHEMBL6445997 0.93 ALOX15 (0.53) GNPATALOX15BLMKDM4EMAPT
SCHEMBL7048124 0.91 ALOX15 (0.52) GNPATALOX15BLMKDM4EMAPT
SCHEMBL31436738 0.91 ALOX15 (0.52) GNPATALOX15BLMKDM4EMAPT
SCHEMBL147914 0.91 ALOX15 (0.52) GNPATALOX15BLMKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120407691-B Text2SQL data set generation method based on dynamic difficulty adjustment HANGZHOU DIANZI UNIVERSITY (CN) 2026-05-26 CN claimed
EP-4737566-A1 CAS12 PROTEIN AND USE THEREOF Reforgene Medicine (CN) 2026-05-06 EP claimed
EP-4692338-A1 CAS12 PROTEIN AND USE THEREOF Guangzhou Reforgene Medicine Co., Ltd. (CN) 2026-02-11 EP claimed
EP-4111165-B1 METHOD AND SYSTEM FOR THE OPTICAL MEASUREMENT OF A PROPERTY OF PARTICLES PRESENT IN A GASEOUS MEDIUM IFP ENERGIES NOW (FR) 2025-11-19 EP claimed
WO-2025080751-A2 ANTI-CDH17 ANTIGEN-BINDING PROTEINS AND USES THEREOF ODYSSEY THERAPEUTICS, INC. (US) 2025-04-17 WO claimed
WO-2025061113-A1 CAS12 PROTEIN AND USE THEREOF 广州瑞风生物科技有限公司 2025-03-27 WO claimed
CN-119628074-A Distributed power supply cluster scheduling method based on NJW spectral clustering algorithm 国网黑龙江省电力有限公司经济技术研究院 2025-03-14 CN claimed
WO-2024078645-A2 CAS PROTEIN AND USE THEREOF 广州瑞风生物科技有限公司 2024-04-18 WO claimed
EP-4128715-A1 DATA ACQUISITION DEVICE FOR MOBILE DEVICES, METHOD FOR CONDUCTING A PRELIMINARY ANALYSIS IN A DATA ACQUISITION DEVICE, VEHICLE, AND COMPUTER PROGRAM DESIGNED ACCORDINGLY ZF CV Systems Global GmbH (CH) 2023-02-08 EP claimed
EP-4111165-A1 METHOD AND SYSTEM FOR THE OPTICAL MEASUREMENT OF A PROPERTY OF PARTICLES PRESENT IN A GASEOUS MEDIUM IFP Energies nouvelles (FR) 2023-01-04 EP claimed
EP-3303507-B1 SUSPENDING AGENTS OBTAINED BY MICELLAR POLYMERIZATION RHODIA OPERATIONS (FR) 2022-08-10 EP claimed
US-20220160898-A1 AN OPTIMIZED ACCEPTOR SPLICE SITE MODULE FOR BIOLOGICAL AND BIOTECHNOLOGICAL APPLICATIONS VIGENERON GMBH (DE) 2022-05-26 US claimed
US-20260146265-A1 CAS12 PROTEINS AND USES THEREOF REFORGENE MEDICINE (CN) 2026-05-28 US disclosed
CN-120407691-B Text2SQL data set generation method based on dynamic difficulty adjustment HANGZHOU DIANZI UNIVERSITY (CN) 2026-05-26 CN disclosed
US-12630598-B2 IL-10 muteins and fusion proteins thereof AMGEN INC. (US) 2026-05-19 US disclosed
CN-122022360-A Auxiliary service-oriented distributed resource cluster regulation and control characteristic evaluation method and system 国网电商科技有限公司 2026-05-12 CN disclosed
US-8258343-B1 Prevention of cellular senescence in mammals by natural peptide complexes ISLAND KINETICS, INC. (US) 2012-09-04 US disclosed
US-8212076-B2 Prevention of cellular senescence in mammals by natural peptide complexes Covalence, Inc. (US) 2012-07-03 US disclosed
US-20110190202-A1 Prevention of Cellular Senescence in Mammals by Natural Peptide Complexes ISLAND KINETICS INC. (US) 2011-08-04 US disclosed
US-20110124573-A1 Osmoprotective Complexes for Prevention of Intra-cellular Dehydration in Mammals ISLAND KINETICS INC. (US) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260146265-A1 CAS12 PROTEINS AND USES THEREOF PHAX, STING1, TTLL12 GNPAT 4519/4885ALOX15 4830/4885BLM 460/4885
US-20110124573-A1 Osmoprotective Complexes for Prevention of Intra-cellular Dehydration in Mammals GLS2, GOT2, COL14A1 GNPAT 2551/4885ALOX15 167/4885BLM 1058/4885
US-12630598-B2 IL-10 muteins and fusion proteins thereof MYH10, IL36G, S100A10 GNPAT 4773/4885ALOX15 3717/4885BLM 1622/4885
US-20110190202-A1 Prevention of Cellular Senescence in Mammals by Natural Peptide Complexes COL14A1, TP53, CUTA GNPAT 3243/4885ALOX15 1107/4885BLM 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.